Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P480

Efficacy of switching to pH-dependent release formulation of mesalazine at 3.6 g/day from time-dependent release formulation of mesalazine at 4.0 g/day in patients with Ulcerative Colitis

Authors:

S. Motoya*, H. Tanaka, M. Miyakawa, R. Sakemi, M. Nasuno, A. Imamura

Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan

P481.

Failure of infliximab treatment in Crohn's disease is associated with the presence of fibrosis

Authors:

J. de Bruyn1,2, S. Meijer3, M. Wildenberg2, G. van den Brink1,2, G. D'Haens1, 1Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands, 2Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, 3Academic Medical Center, Pathology, Amsterdam, Netherlands

P481. Impact of serum drug level and human anti-drug antibody measurement on management of biologic drugs in inflammatory bowel disease
Authors:

A. Jauregui-Amezaga1, I. Ordas1, M. Gallego1, A. Ramirez1, S. Pino1, M.C. Masamunt1, M. Juan2, E. Ricart1, J. Yagüe2, J. Panés1, 1Hospital Clínic i Provincial, Gastroenterology, Barcelona, Spain, 2Hospital Clínic i Provincial, Immunology, Barcelona, Spain

P481

A Scandinavian prospective observational study of iron isomaltoside 1000 treatment: Clinical practice and outcomes in iron deficiency anaemia in patients with IBD

Authors:

S.O. Frigstad*1, T. Rannem2, P.M. Hellstrom3, P. Hammarlund4, O. Bonderup5

1Vestre Viken Hospital Trust, Baerum Hospital Medical Division, Drammen, Norway, 2Nordsjaellands Hospital, Department of gastroenterology, Hilleroed, Denmark, 3Uppsala University Hospital, Department of Medical Sciences, Uppsala, Sweden, 4Angelholms Hospital, Medical Division, Angelholm, Sweden, 5Regional Hospital of Silkeborg, Diagnostisk Center, Silkeborg, Denmark

P482.

Faecal calprotectin can be used to monitor response to therapy in anti-TNF treated patients with Crohn's disease

Authors:

R. Saleem, P. Dubois, G. Chung-Faye, I. Bjarnason, B. Hayee, King's College Hospital NHS Foundation Trust, Gastroenterology, London, United Kingdom

P482. Impact of cytomegalovirus reactivation treatment on inflammatory bowel disease flare
Authors:

M. Delvincourt1, A. Lopez2, S. Pillet2, A. Bourrier1, P. Seksik1, J. Cosnes1, F. Carrat3, J. Gozlan4, L. Beaugerie1, X. Roblin5, L. Peyrin-Biroulet2, H. Sokol1, 1APHP St Antoine Hospital, Gastroenterology, Paris, France, 2Nancy Hospital, Gastroenterology, Nancy, France, 3APHP St Antoine Hospital, Public health, Paris, France, 4APHP St Antoine Hospital, Virology, Paris, France, 5Saint Etienne Hospital, Gastroenterology, France

P482

Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease: estimation of individual pharmacokinetic parameters and trough levels prediction

Authors:

J. Guardiola*1, L. Rodriguez-Alonso1, E. Santacana2, N. Padullés2, H. Colom3, A. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, S. Cobo2, J. Bas4, J. Climent4, F. Morandeira4, F. Rodriguez-Moranta1

1Hospital Universitario de Bellvitge, Gastroenterology, L´Hospitalet de Llobregat, Spain, 2Hospital Universitario de Bellvitge, Pharmacy, L´Hospitalet de Llobregat, Spain, 3Barcelona University, Pharmacokinetics. School of Pharmacy, Barcelona, Spain, 4Hospital Universitario de Bellvitge, Immunology, L´Hospitalet de Llobregat, Spain

P483.

Faecal calprotectin exhibits diurnal variation in inflammatory bowel disease patients but is not affected by time of day

Authors:

C. Dobrzanski1, N. Pedersen1, V. Voxen Hansen2, H. Fuglsang2, L.V. Lennert1, P. Munkholm1, 1Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark, 2Herlev University Hospital, Gastroenterology Research Laboratory, Copenhagen, Denmark

P483. Impact of inflammatory bowel disease nurse specialist on quality of the patient journey
Authors:

K. Kemp1, E. Fernandez2, I. Arnott3, 1University of Manchester/Manchester Royal Infirmary, School of Nursing/Gastroenterology, Manchester, United Kingdom, 2Royal College of Physicians, Clinical Standards Department, London, United Kingdom, 3Western General Hospital, Gastroenterology, Edinburgh, United Kingdom

P483

ABO blood group in monitoring response to infliximab treatment for Crohn's Disease

Authors:

Q. Yu*, L. Wang, L. Li, S. Zhang, M. Chen

The First Affiliated Hospital of Sun Yat-Sen University, Gastroenterology, Guangzhou, China

P484.

Functional cellular based assay reveals neutralising anti-drug antibodies in IBD patients treated with maintenance adalimumab

Authors:

N. Vande Casteele1, M. Peeters1, M. Ferrante2, G. Compernolle1, G. Van Assche2, S. Vermeire2, A. Gils1, 1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID), Leuven, Belgium

P484. Identification of clinical and genetic predictors of response to therapy in patients with ulcerative colitis (UC)
Authors:

P. Ferreira1, P. Sousa2, P. Moura Santos2, P. Ministro3, J. de Deus4, L. Tavares2, P. Peixe5, J. Velosa2, M. Brito1, M. Cravo6, 1Escola Superior de Tecnologia da Saúde de Lisboa, Lisboa, Portugal, 2Hospital Santa Maria, Lisboa, Portugal, 3Hospital S. Teotónio, Viseu, Portugal, 4Hospital Fernando Fonseca, Lisboa, Portugal, 5Hospital Egas Moniz, Lisboa, Portugal, 6Hospital Beatriz Ângelo, Loures, Portugal

P484

Is topical therapy necessary for patients with acute mild and/or moderately active extensive or left-sided Ulcerative Colitis treated with mmx-mesalazine? A pilot, single-center, faecal calprotectin-guided study

Authors:

P. Karatzas, E. Archavlis, A. Christidou, N. Kyriakos, X. Tzannetakou, I. Internos, S. Anastasiadis, L. Varytimiadis, P. Konstantopoulos, I. Drougas, G.J. Mantzaris*

Evangelismos Hospital, Gastroenterology Department, Athens, Greece

P485.

Fecal lactoferrin, calprotectin, PMN-elastase, CRP and white blood count as indicator for clinical course of disease and mucosal healing in patients with ulcerative colitis: A prospective 12-month monitoring study

Authors:

J. Langhorst1, J.H. Boone2, R. Lauche3, A. Rüffer4, G.J. Dobos3, 1University Duisburg-Essen, Kliniken Essen-Mitte, Integrative Gastroenterology, Essen, Germany, 2TechLab Inc., Virginia, Blacksburg, United States, 3University Duisburg-Essen, Kliniken Essen-Mitte, Internal and Integrative Medicine, Essen, Germany, 4Labor L+S, Enterosan, Bad Bocklet-Großenbrach, Germany

P485. IV iron treatment of iron deficiency anaemia with Ferumoxytol in patients with gastrointestinal disorders unable to take oral iron: a randomized controlled trial versus iron sucrose
Authors:

D. Hetzel1, W. Strauss2, K. Bernard3, J. Li3, L. Allen3, 1Royal Adelaide Hospital, Gastroenterology & Hepatology, Adelaide, Australia, 2AMAG pharmaceuticals Inc, Medical Director, Lexington MA, United States, 3AMAG pharmaceuticals Inc, Lexington MA, United States

P485

Pregnancy and its outcomes in female IBD patients.

Authors:

S. Chetcuti Zammit1, M. Caruana1, K.H. Katsanos2, G.J. Mantzaris3, M. Cesarini4, U. Kopylov5, L. Zammit1, P. Ellul*1

1Mater Dei Hospital, Department of Gastroenterology, Msida, Malta, 2University of Ioannina School of Medical Sciences, Department of Internal Medicine, Medical School, Ioannina, Greece, 3Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Department of Gastroenterology, Athens, Greece, 4Sapienza University of Rome, Dipartimento di Medicina Interna e Specialità' Mediche, Rome, Italy, 5Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel

P486.

Factors influencing the time to and outcome of dose escalation of adalimumab in Crohn's disease patients who achieved steroid-free remission on adalimumab

Authors:

G.J. Mantzaris1, N. Kyriakos1, K. Papamichael1, E. Archavlis1, X. Tzannetakou1, I. Internos1, S. Anastasiadis1, P. Karatzas1, D. Tsironikos1, I. Drougas1,2, 1Evangelismos Hospital, A' Department of Gastroenterology, Athens, Greece, 2Evangelismos-Polykliniki-Ophthalmiatreion Hospital, A' Department of Gastroenterology, Athens, Greece

P486. Intravenous corticosteroids in moderate active ulcerative colitis not responding to oral corticosteroids
Authors:

J. Llaó1, J.E. Naves2, A. Ruiz-Cerulla3, L. Marín2, M. Mañosa4, L. Rodríguez-Alonso3, E. Cabré4, E. Garcia-Planella1, J. Guardiola3, E. Domènech4, 1Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 2Hospital Universitari Germans Trias I Pujol, Dept. of Gastroenterology, Badalona, Spain, 3Hospital Universitari Bellvitge-IDIBELL, Gastroenterology, L'Hospitalet de Llobregat, Spain, 4Hospital Universitari Germans Trias I Pujol-CIBEREHD, Dept. of Gastroenterology, Badalona, Spain

P486

Assay of infliximab trough levels and of total antibodies to infliximab in the management of loss of response

Authors:

L. Guidi*1, M. Marzo1, B. Tolusso2, C. Felice1, G. Andrisani1, S. Canestri2, D. Pugliese1, E. Gremese2, A. Papa1, G.L. Rapaccini1, A. Armuzzi1

1Catholic University, IBD Unit, Complesso Integrato Columbus, Rome, Italy, 2Catholic University, Rheumatology, Complesso Integrato Columbus, Rome, Italy

P487.

Factors influencing recurrence following suspension of biological treatment. Importance of mucosal healing

Authors:

V. Ciria, P. Silva, E. Leo, C. Trigo, M.D. De la Cruz, J.M. Herrera, J.L. Márquez, Hospital Virgen del Rocío, Gastroenterology, Sevilla, Spain